ͼƬ dz̸ҩﴫϵͳоļȵ_ĸƽ̨ܶȭ|ufcôͶע|APP**

ĸƽ̨ܶȭ|ufcôͶע|APP**

ǰλãҳ > ҵ > ҽҩѧ > ҩѧ > >

dz̸ҩﴫϵͳоļȵ

Դ::δ֪ | :ĸƽ̨ܶȭ|ufcôͶע|APP** | Ӱ

ժҪͨĽףصҩﴫϵͳµĽչʽҩϵͳ᳦λҩϵͳͰƼݡ

ؼʣҩﴫϵͳʽҩϵͳ᳦λҩϵͳͰƼ

ҩﴫϵͳ(Drug Delivery Systems,DDS)ϵָڷμĹõĸҩIJͬҩʽ60ǰҩѧгΪ͡עƬҼƬȡſѧĽ͵ķչԶԶԽԭеںҪҩﴫϵͳҩ(Device)Աԭҩ븨Ƴɵĸּ㲻ٴƵҪеĽҩƳעϵͳãеѺϽƳɸҩֲӦãʹٴҩ뻯Ϊ˷ͨƼЧѪŨάʱ̵ȱݣ˳ЧעڷЧҩϵͳ/ƼƤҩϵͳһϵµƼڻ/Ƽص㣬гǰáƼָͨڷҩڻڻͷҩʹЧѪŨά൱ʱƼƼϵָҩٶȽܸҩϵͳĿƣpHøӡθ䶯صӰ1ݣǰƺõijҩƼ㼶ҩ͸ãҩ΢裬᳦λҩƬԼԶҩȵظҩȵȡЩ׶Ի͡Ƽϸ֣ͳΪ/Ƽ

йͬĻ/ƼƷϣƬҡ˨͸á͸ƤƬҩֲճĤճעȶʽԿڷ/Ƽչ졣΢轺Ҽ뻺Ƭȣаȫϵߵص㣬һϰ΢ɣиСθѸٱҩӰ΢СģƬб䵥μͨƼDzԶˣһ΢轺Ҳ׶θĻ߷ͷŵԼθҺpHֵ仯ĸӰ졣ˣ΢轺ұȻƬзչǰ

ҹ1977йҩ˷Ѫ没ûʳƻƬⷽоֱ80ű㷺ӡ1995ҹ׼Ļ/Ƽ7֬塢΢򡢺΢΢ɢҩϵͳԼ᳦λҩϵͳڷҩƼоҲܻԾ(Ŀǰ֬׼Ʒ)¼и

1ͻ/Ƽоſ

1.1θͿ͸ҩϵͳ23ݡɲйס

1.2ʽҩϵͳʱҩѧоҩáӦڹ̾ʱɣѳΪƶʱҩƼҪݡҩʽҹɱ仯Ĺɣǽҩѧоһҩģʽжҩҵоʽҩϵͳѿʼо

ҩϵͳ(pulsatile release system)ڷʱʱصķʽθضλͷҩҩϵͳرҹѺҪһѪŨֵļ(ʧߡؽסֲȱѪಡ)Ҳڳ²λҩյЩ(᳦Խ᳦סڷ)ĿǰͶоҪƽҩѪҩH2ϼȵصȡעĿALZA˾Searle˾ͬάҹҩϵͳƷΪCalan- OROSʵ֤ѪѹѸҩʱΪ峿3ңʱڶӰˮƽߣࡢѪǿܳ⣬øҩϵͳ˯ǰã峿ͷҩʮַϸòɱ仯ҪԤƸüͺܿ켴С

1.2.1ҩƬʱر(time-controlled disintegration mechanism)ƵһָѹƬɴҩ֮ĿġƬоҩɣˮ͸СĸϲɡǺˮ͸Լɿҩʱ䡣磺?NFDA1?ͪΪģҩ(ڽϿθڿɱ)ѡȼ׻άظ(ECG-505)Ӳ֬þΪ󻬼ѹƳƬо⻯(HCO)ϩ(PVC);Ҷ(PEG6000)ɣ9094ڷȡ20ĿԸѹ·ƬPEGǺȼɿˮ͸ʡϵͳƽʱΪ(7±1)hʱҩ15 minͷϡ

1.2.2ҩ΢4ݡʱرϵͳ(time-controlled explosion systemTES)΢Ľṹɷ4㣬ﵽоҩ㡢ͼ㼰ˮԾۺĤͼ1ˮͨĤϵͳ͸ӴͼһˮͼĤĿǿʱĤʼѣҩͷšͨıĤĺͷҩʱ䡣磬о(nonpareil)ΰҩ㡢Ͳ(L-HPC)ECĤͲ(180 μm)̶ʱECĤĺȿӰҩʱ(tL)θTESECĤΪ20 μmʱtLΪ1 hECĤΪ25 μmʱtLΪ2 hECĤΪ30 μmʱtLΪ3hECĤ(25 μm)̶L-HPCĺɵҩʱ䣬tiap ride hydrochloride TES,L-HPCΪ120 μmʱ1hʱͺҩĤ6hҲδƣL-HPCΪ180 μmʱ2hĤʼѣ6hȫƣҩͷͬСTESڸʲͬҩҩϵͳѿʼо

1.3᳦λҩϵͳ511ݡ᳦λԽ᳦ס᳦Ҫڽ᳦λҩ⣬﹤̵ķչࡢҩ࣬ҩͨҪעҩθ϶ȶԼòʲ˿ڷڽ᳦ν⵰׵ø٣ýϺãƳɽ᳦λҩϵͳࡢҩڷҩϣƿ͸ҩϵͳҩϵͳͨмֲƳɡ

1.3.1pHеijܲϡ˫Ĥҩڽ᳦λͷš磺ʹ(25%W/W)(62%W/W)(10%W /W)ȣ10%(W/V)PVPˮҺʪ551%M.SΦ 4.5 mmѹƬHPMC²(35.7%䷽ΪMethocel K15 5.0,PEG400 1.0,Talc 2.0,PVP 2.5Ҵ84.0ˮ5.5)ٰ²(5%䷽Ϊ8%(W/V)Eudragitl,2%DEP)ܳpHֵ仯Ӱ졣

1.3.2ʱͲϡͨʳθСֱԼ3hңʳ᳦Լ57hܿ57hҩ߼ɴ᳦ҩ֮Чǰʱҩϵͳ࣬ҩϵͳθſʲͬԸϴ

1.3.3øͲϡý᳦λе΢øԽ߷Ӳ϶ҩ磬żۺȿɱ᳦е΢øҩϽ᳦λרԽǰǿ

1.3.4øƵңڽװһ΢ȦڸƵųȦѶҩ

1.4Զڸҩϵͳ1213ݡɲйס

2ҩϵͳо״

ٴƼĹҪҩİԣ޶ȵǿҩЧͬʱʹҩIJӦͣ˰ҩϵͳ(TDDS)ѳΪִҩѧҪݡͨɽƼֳࣺһרоοƼҩͷŵٶȣ㼶һʽҩֻԵʽҩȵ(ǰ)һרоοƼҩͷŵȥһҪߡѶȸƼڰƼеۡ

2.1ҩƼķ

2.1.1ҩ;֡ȫðҩƼͨڷעȷʽҩʹҩﵼ跢õIJλȫõİҩƼֲҩҩڸòλá

2.1.2÷ʽ֡(active targeting)ҩƼʶ֯ϸĴӣΪ(passive targeting)ҩƼ֬塢΢򡢺΢΢Ƽ԰ϸʶɾѪѭDzͨëϸѪܴڸòλҩ

2.1.3ҩˮƽ֡һ΢Ƽֻܽҩض٣ϵָܽҩijٵضλϵָܽҩضλIJϸڡܽҩƳƼʹҩϸˮƽϷãҩרŹϸϸûл򼸺ûвӰ죬ʹҩЧﵽij̶ȡ

2.1.4̬֡ˮƼָ֬塢΢򡢺΢ˮ΢ƼһˮԵԴƼϳɴȻ(۶ǡ塢ǡ)ƼҩİҪƾϵͳʵֿ֣ɳΪҩϵͳ (drug-carrier systems)

Ͼ뱻ҩƼķ෨

оУҩо϶࣬֬΢Ƽ󣬿ɰСֲڲͬע712 μm΢ɱβеԽ˶ȡע12 μm΢ëϸѪܴΡУǻע0.10.2 μm΢ܿ챻״Ƥϵͳ(RES)ľϸյݷϸøС

2.2ҩϵͳչơΪһҩİԣ1415ݣѧֽʶϸĴҩı(ҩֱ)磺¡ںҩ֬(΢)ı棬ҩϸİԣʵѪڲЧǶϿϸ˵¡(chTNT)֬壬ʹʵڵЧȵ֬Ϊߣ֬ΪҩﴫϵͳоΪ࣬Ŀǰܹѧߵձע

оϸϵҶ壬ͻϾϸö࣬ƱҶ֬壬ҶΪ鵼֬ϸİԡ

Ҷ֬׵“”ϸĤΪҩϵͳchTNT-֬״͸“”ϸĤϸˣΪҩϵͳֲͬİ֬ƲͬڵĹ

1966Morellȷֲ鶯ĸʵϸĤȥҺǵ(Asialoglycoprotein receptor,ASGPr)רһԵʶ԰Ϊ˻ǵףǵΪ壬ɽҩﵼʵϸ(ηʵϸ(ݷϸƤϸ)ıи¶)ϸøתˣ屾»صϸĤ

ĿǰͰƼо϶ֽ࣬ͨ鵼ʽҩİԣʹҩЧӵãӦС

ɽҩƳɴƼҩİԣ纬΢ᰢùص΢򣬶עڰų£ҩŨȱȾעͬ밢ùظ߳100ٴƼеĴԳ΢ӿԶڰȫرų⡣дڴųǿȡݶ“۽”⣬ųǷıϸĻܺ͸ıѪķʽ⣬дһо

ܶ֬(LDL)16Ǵڲ鶯Ѫе֬סѪLDLЯѪ̴2/3ϸԴԵ̴ҪԴLDLڴлҪϸĤLDLʶ𣬴ӶϸڱãϸڵԴԵ̴ҪʱͨϸĤLDLĿͻԣӶLDLնӶԴԵ̴áLDLҪضLDLϸԴԵ̴ϳϰֳƣϸĤԵ̴ĴϸLDLĻԼijЩϸи߳ϸ20ϣˣLDLؿҩɴ߶ijЩϸİԡLDLԴ֬ףΪҩ壬ɱ֬塢¡ѭб״ƤϵͳѸ⣬ֲֿһڵİԲIJ㣬ԽǰҩﻯдڵİԲӦҪ塣

ϸСҩ΢ѭʱױRESľϸɣӶӰҩﵽƵİʴˣرRESѳΪҩԵص֮һ1718ݡհRESͣȻٸҩ壬ֱ˾ٻʹ߹𣬲鷢ʴ˷ȡԻԴLDLΪ壬ɻرRESɡо϶ǻرRES֬(RES-avoiding immunoliposomes)ںҩ֬ıIgG߿壬ֹPEGͼ2Ȼر˾ϸɣֿɽҩﵼϸPEGɻرRESɵĻδȫ壬PEGӾ߶ؽṹйأǿˮԺһйأƲPGEģ°ϸϸڵĶǻĹܡرRESķӱԼ(nonionic surfactant vesicles,NsVsNiosomes)PEG2000-̴(PEG-ch)ƳɵijѭùطӱԼ(long circulation adriamycin NsVs,L-ADM-NsVs)ϵPEGǿ˸ݵˮԣӶRESɣӳѪѭʱ䣬߰Ժԡ

ο

1Ansel HC,Popovich NG,Allen LV.Pharmaceutical dosage forms and drug delivery systems.Williams & Wilkins Baltimore.6th ed.New York:Marcel Dekker Inc,1995.218220

2Deshpande AA,Shah NH,Rhodes CT,et al.Development of a novel controlled-release system for gastric retention.Pharm Res,1997,14(6)815

3Shalaby WSW,Blevins WE,Park K.In vitro and in vivo studies of enzyme-digesbible hydrogels for oral drug delivery.J Controlled Release,1992,19(13)131

4Ueda S,Yamagulchi H,Kotani M,et al.Development of a novel drug release system,time-controlled explosion system(TES).Chem Pharm Bull,1994,42(4)246

5Bieck PR.Colonic drug absorption and metabolism.New York:Marcel Dekker Inc,1993.169172

6Gazzanig A,Sangalli ME,Giordano F.Oral chronotopic drug delivery systems:achievement of time and/or sit specifity.Eur J Pharm Biopharm,1994,40(4)246

7Rubinstein A,Radai R,Ezra M,et al.In vitro evaluation of calcium pectinate:a potential colon-specific drug delivery carrier.Pharm Res,1993,10(2)258

8Ashford M,Fell J,Attwood D,et al.Studies on pectin formulations for colonic drug delivery.J Controlled Release,1994,30(3)225

9Leopold CS,Friend DR.A dexamethasone-poly (L-aspartic acid) conjugate as potential prodrug for colon-specific drug delivery.Eur J Pharm Biopharm,1996,42(Suppl 1)S485

10Bieck PR.Colonic drug absorption and metabolism.New York:Marcel Dekker Inc,1993.145148

11Sako K,Nakashima H,Sawada T,et al.Relationship between gelation rate of controlled-release acetaminophen tablets containing ployethylene oxide and colonic drug release in dogs.Pharm Res,1996,13(4)549

12Anderson JM,Kim SW,Kopech J,et al.Advances in drug delivery systems 5.LondonNew York,Tokyo:Elsevier Amsterdam,1992.145159

13Kitano S,Koyamay ,Kataoka K,et al.A novel drug delivery system utilizing a glucose responsive polymer complex between poly(vinyl alcohol)and poly(N-vinl-2-pyrrolidone)with a phenylboronic acid moiety.J Controlled Release,1992,19(13)161

14Gottschalk S,Cristiano RJ,Smith LC,et al.Folate receptor mediated DNA delivery into tumor cells:potosomal disruption results in enhanced gene expression.Gene Ther,1994,1(1)185

15Rojansakuly.Antisense oligonucleotide therapeutics:drug delivery and targeting.Adv Drug Delivery Rev,1996,18(2)115

16Bijsterbosch MK,Berkel TJCV.Native and modified lipoproteins as drug delivery systems.Adv Drug Delivery Rev,1990,5(3)231

17Herron JN,Gentry CA,Davies SS,et al.Antibodies as targeting moiesties:affinity measurements conjugation chemistry and applications in immanoliposomes.J Controlled Release,1994,28(13)155

18Kuke I,Hayashi T,Tabata Y,et al.Synthesis of poly (ethylene glycol)derivatives with different branchings and their use for protein modification.J Controlled Release,1994,30(1)27


ĸƽ̨ܶȭ|ufcôͶע|APP**